相关实验视频
Updated: Jun 11, 2025

07:22
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
8.1K
过敏原免疫疗法用于预防和治疗喘
Thierry Batard1, Camille Taillé2,3, Laurent Guilleminault4,5,6
1Innovation & Science Department, Stallergenes Greer, Antony, France.
概括
过敏原免疫疗法 (AIT) 是唯一可以改善过敏喘症状并防止疾病恶化的治疗方法. 将AIT与生物药物结合起来,为严重过敏喘管理提供了新的选择.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
- 过敏 过敏是一种过敏.
背景情况:
- 过敏性喘很常见,传统的治疗方法并不能控制所有患者的症状.
- 生物疗法有助于一些人,但并不能解决所有未满足的需求或修改疾病.
- 目前的治疗方法缺乏疾病修饰性质,突出显示需要新的方法.
研究的目的:
- 审查过敏原免疫疗法 (AIT) 在治疗过敏性喘中的作用.
- 评估AIT的疾病修饰免疫效应和临床试验证据.
- 探索AIT和生物药物用于严重过敏喘的组合疗法.
主要方法:
- 对过敏性喘的过敏原免疫治疗临床试验的系统审查.
- 对AIT的免疫效应和疾病修饰性能的分析.
- 对AIT和组合疗法的安全性和疗效数据的评估.
主要成果:
- 临床试验支持AIT作为一种独特的治疗方法,可以改善过敏喘症状.
- 艾滋病治疗是预防过敏性喘发作和恶化的唯一选择.
- 与AIT和生物药物联合治疗对严重过敏性喘有很大的前景.
结论:
- 过敏原免疫疗法是一种疾病修饰治疗,对于过敏喘管理至关重要.
- AIT可以改善症状并防止疾病的进展,解决未满足的需求.
- 结合AIT和生物疗法代表了严重过敏喘的有希望的未来方向.
更多相关视频
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
241
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
241
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Allergic Reactions
27.3K
Overview
27.3K
Asthma: Pathogenesis and Management
363
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
363
Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K

